Blue Shield’s Expensive Quest for Non-Toxic PBMs, GLP-1 "Mega-Blockbusters" Mask Rotting R&D Returns, and CVS Masters Corporate Efficiency While Aetna Dodges High-Cost Members

Hey all, 

Happy Monday! Welcome to the latest exhibit of our healthcare system’s descent into functional madness, where Blue Shield of California is currently forced to hire a small army of five specialized vendors just to untangle the knot of "efficiency" tied by traditional PBMs. It’s a bold new era of R&D where, if you strip away the GLP-1 weight-loss craze, you’d literally earn a better return on your capital putting it in a boring local CD than gambling $2.6 billion on the rest of pharmaceutical "innovation." Ultimately, as incumbents like CVS continue to extract their "middleman tax" to the tune of $100 billion in revenue, it’s becoming painfully clear that the only thing these traditional players are lowering is our collective expectation that the system will ever actually prioritize patients over spreadsheets.

Enjoy the rundown!

Jacob Brody (Co-Founder & CEO, ZorroRX)

[Modern Healthcare] Inside Blue Shield of California’s $500M PBM experiment

Blue Shield of California has successfully captured $100 million in savings through its modular pharmacy model, though the full $500 million goal remains elusive as the company navigates the complexities of direct manufacturer contracting. Despite improved member satisfaction and the successful rollout of new vendors like Amazon Pharmacy, the insurer had to sideline Mark Cuban’s Cost Plus Drugs because the startup’s retail footprint couldn't clear California's rigorous regulatory hurdles. This initiative highlights the sheer absurdity of trying to save money in a healthcare market where the Big 3 PBMs have spent decades engineering a "system" so convoluted that hiring a small army of specialized vendors is considered the simpler, more transparent alternative.

Full Article

[Fierce Healthcare] CVS Health Q1 2026 Earnings and Medicare Advantage Goals

CVS Health exceeded Wall Street expectations in the first quarter of 2026, reporting a $2.9 billion profit and $100.4 billion in revenue driven by improved performance in its insurance and pharmacy divisions. Despite underwhelming Medicare Advantage rate notices from federal regulators, company executives reaffirmed that they remain on track to meet their target margin improvement goals for the program by 2028 through disciplined enrollment strategies and operational focus at Aetna. It’s a masterclass in corporate efficiency where "simplifying healthcare" really means prioritizing a pristine balance sheet, provided those bothersome patients stop inconveniently getting sick and cutting into the quarterly bottom line.

Full Article

[Deloitte] Navigating the GLP-1 Boom and Pharmaceutical R&D Returns

Deloitte’s 16th annual analysis reveals that while pharmaceutical R&D returns rose to a 7.0 percent IRR in 2025, this growth is almost entirely driven by a few high-value GLP-1 and GIP "mega-blockbusters" masking a broader decline in underlying industry productivity. When these obesity-focused assets are excluded, the rate of return drops to just 2.9 percent as the average cost to develop a single drug from discovery to launch has surged to an all-time high of $2.67 billion. Apparently, the grand future of medical innovation is now just three GLP-1 injections in a trench coat pretending to be a healthy industry while executives set fire to $2.6 billion per drug for everything that isn't a miracle weight-loss shot.

Full Article